118 related articles for article (PubMed ID: 10522699)
1. Design, combinatorial chemical synthesis and in vitro characterization of novel urea based gelatinase inhibitors.
Zhang Y; Li D; Houtman JC; Witiak DT; Seltzer J; Bertics PJ; Lauhon CT
Bioorg Med Chem Lett; 1999 Oct; 9(19):2823-6. PubMed ID: 10522699
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design and synthesis of a series of hydroxamic acids with a quaternary-hydroxy group in P1 as inhibitors of matrix metalloproteinases.
Jacobson IC; Reddy PG; Wasserman ZR; Hardman KD; Covington MB; Arner EC; Copeland RA; Decicco CP; Magolda RL
Bioorg Med Chem Lett; 1998 Apr; 8(7):837-42. PubMed ID: 9871551
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and evaluation of matrix metalloprotease inhibitors bearing cyclopropane-derived peptidomimetics as P1' and P2' replacements.
Reichelt A; Gaul C; Frey RR; Kennedy A; Martin SF
J Org Chem; 2002 Jun; 67(12):4062-75. PubMed ID: 12054939
[TBL] [Abstract][Full Text] [Related]
4. Design, synthesis, and structure-activity relationships of macrocyclic hydroxamic acids that inhibit tumor necrosis factor alpha release in vitro and in vivo.
Xue CB; Voss ME; Nelson DJ; Duan JJ; Cherney RJ; Jacobson IC; He X; Roderick J; Chen L; Corbett RL; Wang L; Meyer DT; Kennedy K; DeGradodagger WF; Hardman KD; Teleha CA; Jaffee BD; Liu RQ; Copeland RA; Covington MB; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2001 Aug; 44(16):2636-60. PubMed ID: 11472217
[TBL] [Abstract][Full Text] [Related]
5. Selectivity of inhibition of matrix metalloproteases MMP-3 and MMP-2 by succinyl hydroxamates and their carboxylic acid analogues is dependent on P3' group chirality.
Fray MJ; Burslem MF; Dickinson RP
Bioorg Med Chem Lett; 2001 Feb; 11(4):567-70. PubMed ID: 11229773
[TBL] [Abstract][Full Text] [Related]
6. Discovery of potent and selective succinyl hydroxamate inhibitors of matrix metalloprotease-3 (stromelysin-1).
Fray MJ; Dickinson RP
Bioorg Med Chem Lett; 2001 Feb; 11(4):571-4. PubMed ID: 11229774
[TBL] [Abstract][Full Text] [Related]
7. Design and synthesis of potent hydroxamate inhibitors with increased selectivity within the gelatinase family.
Zapico JM; Puckowska A; Filipiak K; Coderch C; de Pascual-Teresa B; Ramos A
Org Biomol Chem; 2015 Jan; 13(1):142-56. PubMed ID: 25348733
[TBL] [Abstract][Full Text] [Related]
8. Selective inhibition of low affinity IgE receptor (CD23) processing: P1' bicyclomethyl substituents.
Bailey S; Bolognese B; Faller A; Louis-Flamberg P; MacPherson DT; Mayer RJ; Marshall LA; Milner PH; Mistry J; Smith DG; Ward JG
Bioorg Med Chem Lett; 1999 Nov; 9(21):3165-70. PubMed ID: 10560745
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and SAR of bicyclic heteroaryl hydroxamic acid MMP and TACE inhibitors.
Zask A; Gu Y; Albright JD; Du X; Hogan M; Levin JI; Chen JM; Killar LM; Sung A; DiJoseph JF; Sharr MA; Roth CE; Skala S; Jin G; Cowling R; Mohler KM; Barone D; Black R; March C; Skotnicki JS
Bioorg Med Chem Lett; 2003 Apr; 13(8):1487-90. PubMed ID: 12668018
[TBL] [Abstract][Full Text] [Related]
10. beta-N-Biaryl ether sulfonamide hydroxamates as potent gelatinase inhibitors: part 1. Design, synthesis, and lead identification.
Yang SM; Scannevin RH; Wang B; Burke SL; Wilson LJ; Karnachi P; Rhodes KJ; Lagu B; Murray WV
Bioorg Med Chem Lett; 2008 Feb; 18(3):1135-9. PubMed ID: 18086526
[TBL] [Abstract][Full Text] [Related]
11. Molecular docking studies of a group of hydroxamate inhibitors with gelatinase-A by molecular dynamics.
Hou T; Zhang W; Xu X
J Comput Aided Mol Des; 2002 Jan; 16(1):27-41. PubMed ID: 12197664
[TBL] [Abstract][Full Text] [Related]
12. The synthesis and biological activity of a novel series of diazepine MMP inhibitors.
Levin JI; DiJoseph JF; Killar LM; Sung A; Walter T; Sharr MA; Roth CE; Skotnicki JS; Albright JD
Bioorg Med Chem Lett; 1998 Oct; 8(19):2657-62. PubMed ID: 9873598
[TBL] [Abstract][Full Text] [Related]
13. Synthesis and activity of selective MMP inhibitors with an aryl backbone.
Barta TE; Becker DP; Bedell LJ; De Crescenzo GA; McDonald JJ; Munie GE; Rao S; Shieh HS; Stegeman R; Stevens AM; Villamil CI
Bioorg Med Chem Lett; 2000 Dec; 10(24):2815-7. PubMed ID: 11133099
[TBL] [Abstract][Full Text] [Related]
14. Structure--activity relationships of the peptide deformylase inhibitor BB-3497: modification of the P2' and P3' side chains.
Davies SJ; Ayscough AP; Beckett RP; Clements JM; Doel S; Pratt LM; Spavold ZM; Thomas SW; Whittaker M
Bioorg Med Chem Lett; 2003 Aug; 13(16):2715-8. PubMed ID: 12873500
[TBL] [Abstract][Full Text] [Related]
15. Solid-phase synthesis of an arylsulfone hydroxamate library.
Salvino JM; Mathew R; Kiesow T; Narensingh R; Mason HJ; Dodd A; Groneberg R; Burns CJ; McGeehan G; Kline J; Orton E; Tang SY; Morrisette M; Labaudininiere R
Bioorg Med Chem Lett; 2000 Aug; 10(15):1637-40. PubMed ID: 10937713
[TBL] [Abstract][Full Text] [Related]
16. Design and synthesis of selective and blood-brain barrier-permeable hydroxamate-based gelatinase inhibitors.
Bertran A; Khomiak D; Konopka A; Rejmak E; Bulska E; Seco J; Kaczmarek L; Tarragó T; Prades R
Bioorg Chem; 2020 Jan; 94():103365. PubMed ID: 31676116
[TBL] [Abstract][Full Text] [Related]
17. Arylsulphonyl hydroxamic acids: potent and selective matrix metalloproteinase inhibitors.
Baxter AD; Bhogal R; Bird J; Keily JF; Manallack DT; Montana JG; Owen DA; Pitt WR; Watson RJ; Wills RE
Bioorg Med Chem Lett; 2001 Jun; 11(11):1465-8. PubMed ID: 11378378
[TBL] [Abstract][Full Text] [Related]
18. Novel bis-(arylsulfonamide) hydroxamate-based selective MMP inhibitors.
Subramaniam R; Haldar MK; Tobwala S; Ganguly B; Srivastava DK; Mallik S
Bioorg Med Chem Lett; 2008 Jun; 18(11):3333-7. PubMed ID: 18442906
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and evaluation of benzothiadiazepine hydroxamates as selective tumor necrosis factor-alpha converting enzyme inhibitors.
Cherney RJ; Duan JJ; Voss ME; Chen L; Wang L; Meyer DT; Wasserman ZR; Hardman KD; Liu RQ; Covington MB; Qian M; Mandlekar S; Christ DD; Trzaskos JM; Newton RC; Magolda RL; Wexler RR; Decicco CP
J Med Chem; 2003 May; 46(10):1811-23. PubMed ID: 12723945
[TBL] [Abstract][Full Text] [Related]
20. X-ray structures of human neutrophil collagenase complexed with peptide hydroxamate and peptide thiol inhibitors. Implications for substrate binding and rational drug design.
Grams F; Reinemer P; Powers JC; Kleine T; Pieper M; Tschesche H; Huber R; Bode W
Eur J Biochem; 1995 Mar; 228(3):830-41. PubMed ID: 7737183
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
